← back to search

Roberto Pecoits‐Filho

Pontifícia Universidade Católica do Paraná · BR
Area of research
Nephrology · Hematology
Research interest
Research interests include Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes, Erythropoietin and Anemia Treatment, and Acute Kidney Injury Research.
h-index
80
citations
27,939
works
745
NIH funding
primary concept
Medicine
email

Recent publications

Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community
American Journal of Preventive Cardiology 2025cited by 2position: firstdoi
Sex and the Risk of Atheromatous and Nonatheromatous Cardiovascular Disease in CKD: Findings From the CKD-REIN Cohort Study
American Journal of Kidney Diseases 2024cited by 21position: middledoi
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney International 2023cited by 131position: middledoi
Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney International 2023cited by 78position: middledoi
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty
The Journals of Gerontology Series A 2023cited by 40position: middledoi
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
American Journal of Kidney Diseases 2023cited by 27position: middledoi
A new approach for cognitive impairment pattern in chronic kidney disease
Nephrology Dialysis Transplantation 2023cited by 22position: middledoi
International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?
Lipids in Health and Disease 2023cited by 15position: middledoi
Conservative Kidney Management Practice Patterns and Resources in the United States: A Cross-Sectional Analysis of CKDopps (Chronic Kidney Disease Outcomes and Practice Patterns Study) Data
Kidney Medicine 2023cited by 14position: middledoi
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial
Advances in Therapy 2023cited by 8position: middledoi
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
Clinical Kidney Journal 2022cited by 96position: middledoi
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms
American Journal of Kidney Diseases 2022cited by 87position: lastdoi
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
Nephrology Dialysis Transplantation 2022cited by 74position: middledoi
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort
Clinical Kidney Journal 2022cited by 36position: middledoi
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility
Kidney International Reports 2022cited by 34position: middledoi
Barriers to conservative care from patients’ and nephrologists’ perspectives: the CKD-REIN study
Nephrology Dialysis Transplantation 2022cited by 24position: middledoi
Five-Year Symptom Trajectories in Nondialysis-Dependent CKD Patients
Clinical Journal of the American Society of Nephrology 2022cited by 23position: middledoi
Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients
Kidney360 2022cited by 7position: middledoi
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
Kidney International 2021cited by 387position: middledoi
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Kidney International 2021cited by 333position: middledoi
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Kidney International 2021cited by 208position: middledoi
How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
Clinical Kidney Journal 2021cited by 80position: middledoi
Nephrologists’ Perspectives on Gender Disparities in CKD and Dialysis
Kidney International Reports 2021cited by 68position: middledoi
Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline
Annals of Internal Medicine 2021cited by 66position: middledoi
Workforce capacity for the care of patients with kidney failure across world countries and regions
BMJ Global Health 2021cited by 58position: middledoi
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America
Kidney International Supplements 2021cited by 39position: middledoi
Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD
Current Cardiology Reports 2021cited by 20position: middledoi
Urgent-start dialysis in patients referred early to a nephrologist—the CKD-REIN prospective cohort study
Nephrology Dialysis Transplantation 2021cited by 16position: middledoi
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD
Clinical Journal of the American Society of Nephrology 2021cited by 12position: middledoi
Abstract 52: KDIGO (Kidney Disease: Improving Global Outcomes) Guideline Update On The Management Of Blood Pressure In Chronic Kidney Disease: What’s New And What’s Different From Other Guidelines
Hypertension 2021cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David W. Johnson · Mitsubishi Chemical (Germany)8 papers (2016–2021)Jonathan C. Craig · Murdoch Children's Research Institute6 papers (2017–2021)Johannes F.E. Mann · Friedrich-Alexander-Universität Erlangen-Nürnberg6 papers (2020–2021)Juan Jesús Carrero · Danderyds sjukhus6 papers (2020–2022)David C. Wheeler · University College London5 papers (2021–2023)Csaba P. Kövesdy · RELX Group (United States)5 papers (2021–2023)Martin Howell · University of Technology Sydney5 papers (2017–2021)Catherine M. Clase · McMaster University5 papers (2020–2022)Carol A. Pollock · Macquarie University5 papers (2017–2023)Fan Fan Hou · Guangdong Academy of Sciences5 papers (2021–2021)Marcello Tonelli · Institute of Public Health Zadar5 papers (2021–2021)Allison Tong · Brigham and Women's Hospital4 papers (2017–2021)Greg Knoll · Ottawa Hospital4 papers (2021–2021)Alfred K. Cheung · University of Utah4 papers (2021–2021)Susan L. Furth · Institute for Medical Informatics and Biostatistics4 papers (2021–2021)Paul Muntner · Diagnostics for the Real World (United States)4 papers (2021–2021)Peter Rossing · University of Glasgow4 papers (2021–2023)Charles Tomson · Freeman Hospital4 papers (2021–2021)William C. Cushman · University of Tennessee Health Science Center4 papers (2021–2021)Bruce Robinson · University of Minnesota Medical Center4 papers (2020–2023)